Tekmira, NCI Publish Preclinical Data on siRNA Knockdown of Liver Cancer Target

The publication comes about five months after the company hinted that it might test its investigational cancer treatment TKM-PLK1, which is already in phase I testing for solid tumors outside the liver, as a treatment for the disease in a new clinical trial with the NCI.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.